This major investment will identify a strong and reliable long-term source and its leading position in polios, the company said.
In a challenging and changing environment, Roquette said it remains deeply committed to modernizing its facilities. Investing in polios was and remains a strategic resolution for the organization in order to better meet the long-term expectations of its customers.
The Lestrem de Roquette site is the largest polyol factory in the world offering a wide variety of products. According to the company, this investment will improve the power of the devices and develop protection standards. It will also make it possible to standardize certain business operations that contribute to an overall improvement in production performance. This evolution will ensure a sustainable source in the market and meet the growing expectations of consumers for greater flexibility.
However, polyols can cause digestive discomfort if administered in excess, and their use requires a precautionary label about laxative effects on product packaging. Polyols like xylitol and erythritol, on the other hand, can have a laxative effect if given in gigantic amounts and have man-made-sounding names that may have been avoided by consumers.
Polyols are also key excipients for the pharmaceutical industry and ingredients for oral care applications.
Pascal Leroy, Senior Vice President of Core Ingredients at Roquette, said: “Today, Roquette identifies itself as a world leader in polyols. We are well positioned to meet the wishes of visitors as we try to be the most productive partner for the polio markets, providing a wide range, very well adapted to all markets and assisted through a global network of service and technical assistance. With this investment, we will now gain reliability and our global business footprint.